Comp Set INDGN SYNGENE× LTTS× GRANULES× + JUBLPHARMA + KIMS + ERIS + EMCURE + ONESOURCE + CONCORDBIO + PFIZER + POLYMED + RAINBOW
In ₹ Crore except Per Share
Latest Annual
INDGN
FY26
SYNGENE
FY26
LTTS
FY26
GRANULES
FY26
Peer
Average
Valuation — at last close P/E 35.82× 52.20× ◆ 33.87×34.35× 40.14× -11% P/B 4.59× ◆ 3.42×6.69× 4.10× 4.74× -3% EV/EBITDA 20.88× ◆ 16.63×20.81× 17.90× 18.45× +13% Market Cap ₹14,405 Cr ₹16,553 Cr ₹43,334 Cr ₹20,826 Cr ₹26,904 Cr -46% Growth Revenue CAGR 3Y — 5.40% ◆ 11.12%5.95% 7.49% Revenue CAGR 5Y — 11.35% ◆ 15.07%10.63% 12.35% Net Income CAGR 3Y — -11.98% 2.95% ◆ 4.82%-1.40% Revenue YoY (latest Q) ◆ 39.55%-8.55% 2.04% 22.04% 5.18% +664% Net Income YoY (latest Q) 9.99% -52.01% ◆ 66.68%59.77% 24.81% -60% Profitability EBITDA Margin 17.63% ◆ 24.57%17.60% 22.09% 21.42% -18% Net Income Margin 11.43% 8.47% ◆ 11.65%11.09% 10.40% +10% Return on Common Equity 13.94% 6.62% ◆ 20.38%13.52% 13.51% +3% Return on Capital Employed 15.65% 8.54% ◆ 21.82%18.00% 16.12% -3% Return on Assets 10.10% 4.57% ◆ 12.73%8.52% 8.61% +17% Credit & Quality Total Debt/Equity ◆ 0.00×0.00× 0.00× 0.26× 0.09× -100% Interest Coverage ◆ 25.52×9.54× 24.80× 7.77× 14.04× +82% Scale — latest FY Revenue / Total Income ₹3,511 Cr ₹3,739 Cr ₹10,996 Cr ₹5,366 Cr ₹6,700 Cr -48% Net Income ₹401 Cr ₹317 Cr ₹1,281 Cr ₹595 Cr ₹731 Cr -45% Total Assets ₹4,620 Cr ₹7,055 Cr ₹10,489 Cr ₹7,720 Cr ₹8,421 Cr -45% EPS ₹16.72 ₹7.87 ₹120.71 ₹24.47 ₹51.02 -67% Book Value per Share ₹130.51 ₹120.11 ₹610.63 ₹205.21 ₹311.98 -58%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › » Latest: FY26 · Consolidated CHART » ALPHA AI » COMP » FA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95% .
